Business Context and Reporting Period
This Form 8-K was filed by RXi Pharmaceuticals Corporation (also referred to as Phio Pharmaceuticals Corp. in metadata) on August 17, 2018. The report addresses a specific corporate event regarding the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing references financial data from the Company's Form 10-Q for the period ended June 30, 2018, to substantiate compliance with listing rules.
- Stockholders' Equity: $3,272,000 (as of June 30, 2018).
- Revenue, Profit, Cash Flow, Margins, Debt: The filing text does not provide clear values for these metrics.
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders' equity requirement for continued listing. The company received written notice from the Nasdaq Stock Market confirming it had regained compliance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies beyond the resolution of the listing deficiency. No unusual items were reported in this specific document.
Investor Verification Checklist
- Verify the company's current stockholders' equity against the $3,272,000 figure reported in the June 30, 2018 Form 10-Q.
- Confirm the company's continued listing status on The Nasdaq Capital Market.
- Review the referenced Form 10-Q (filed August 14, 2018) for comprehensive financial performance data not included in this 8-K.